Inari Medical (NARI)
(Delayed Data from NSDQ)
$57.98 USD
+3.18 (5.80%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $58.68 +0.70 (1.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NARI 57.98 +3.18(5.80%)
Will NARI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NARI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NARI
Here's Why You Should Retain Inari Medical (NARI) for Now
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
NARI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inari's (NARI) Expanding Product Portfolio Offsets Competition
Inari Medical (NARI) Sues Truvic on Patent Infringement
Here's Why You Should Retain Inari Medical (NARI) for Now
Other News for NARI
Inari Medical to Announce Second Quarter 2024 Financial Results
Insider Sale: Chief Medical Officer Thomas Tu Sells Shares of Inari Medical Inc (NARI)
Inari Medical's ThomasTu sells over $910K in company shares
Inari Medical price target raised by $13 at Truist, here's why
Class Action Lawsuit Against Inari Medical, Inc. (NASDAQ:NARI)